血管紧张素受体-脑啡肽酶抑制剂在心力衰竭治疗中的研究进展  

Angiotensin Receptor-Neprilysin Inhibitor in Treatment of Heart Failure

作　　者：刘瑞闪 周建中[1] LIU Ruishan;ZHOU Jianzhong(Department of Cardiology,The First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China)

机构地区：[1]重庆医科大学附属第一医院心内科,重庆400016

出　　处：《心血管病学进展》2020年第4期384-387,413,共5页Advances in Cardiovascular Diseases

摘　　要：心力衰竭治疗策略的变化与其病理生理机制的演变是统一的。现通过对神经内分泌机制中利钠肽系统的介绍增加对血管紧张素受体-脑啡肽酶抑制剂的认识,同时对其目前在随机对照研究及真实世界研究取得的进展进行汇总,最后对血管紧张素受体-脑啡肽酶抑制剂的临床应用提出一些思考,以供临床借鉴。The treatment strategy of heart failure is consistent with its evolving pathophysiology.Through the introduction of one of the neuroendocrine mechanism-natriuretic peptides,it can increase the understanding of angiotensin receptor-neprilysin inhibitor( ARNI). At the same time,this review will have a summary of the progress of ARNI in both randomized controlled trial and real world evidence.Finally,some thoughts on its clinical application are put forward for reference.

关 键 词：心力衰竭 利钠肽系统 血管紧张素受体-脑啡肽酶抑制剂 

分 类 号：R541.6[医药卫生—心血管疾病]